Opus Genetics (NASDAQ:IRD) Earns Buy Rating from Chardan Capital

Posted by Stanley Muller on Jul 6th, 2026

Opus Genetics (NASDAQ:IRD – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a report issued on Monday,Benzinga reports. They currently have a $13.00 price target on the stock. Chardan Capital’s price target suggests a potential upside of 200.58% from the company’s previous close.

A number of other research analysts have also commented on IRD. Wall Street Zen lowered Opus Genetics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. B. Riley Financial reaffirmed a “buy” rating on shares of Opus Genetics in a research note on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a research report on Tuesday, April 21st. Citigroup initiated coverage on Opus Genetics in a report on Tuesday, April 28th. They set an “outperform” rating on the stock. Finally, Zacks Research raised shares of Opus Genetics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Opus Genetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.77.

View Our Latest Report on IRD

Opus Genetics Price Performance

Shares of NASDAQ:IRD traded up $0.10 during midday trading on Monday, reaching $4.33. The company had a trading volume of 440,420 shares, compared to its average volume of 948,153. The stock has a market capitalization of $357.12 million, a P/E ratio of -3.25 and a beta of 0.55. The stock’s fifty day moving average price is $4.41 and its 200-day moving average price is $3.85. Opus Genetics has a one year low of $0.98 and a one year high of $5.81.

Opus Genetics (NASDAQ:IRD – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.59). Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 892.36%.The company had revenue of $2.16 million during the quarter, compared to the consensus estimate of $2.93 million. As a group, sell-side analysts forecast that Opus Genetics will post -1.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Ashwath Jayagopal sold 7,542 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $5.19, for a total value of $39,142.98. Following the sale, the insider directly owned 509,233 shares of the company’s stock, valued at approximately $2,642,919.27. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $4.35, for a total value of $7,395,000.00. Following the sale, the director owned 3,792,171 shares of the company’s stock, valued at approximately $16,495,943.85. The trade was a 30.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,738,703 shares of company stock worth $7,596,606 in the last ninety days. 11.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Opus Genetics

Several large investors have recently bought and sold shares of IRD. Nantahala Capital Management LLC lifted its stake in shares of Opus Genetics by 42.9% in the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after buying an additional 1,435,407 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of Opus Genetics during the 4th quarter worth approximately $5,463,000. Millennium Management LLC acquired a new stake in shares of Opus Genetics during the 4th quarter worth approximately $4,025,000. ADAR1 Capital Management LLC increased its position in shares of Opus Genetics by 4,522.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock valued at $8,413,000 after purchasing an additional 1,809,004 shares during the period. Finally, Mink Brook Asset Management LLC raised its stake in shares of Opus Genetics by 34.5% in the fourth quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after purchasing an additional 427,684 shares in the last quarter. 14.97% of the stock is currently owned by institutional investors and hedge funds.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.